MOP (Afghanistan)

The Ministry of Public Health (MoPH), operating through the General Directorate of Pharmaceutical Affairs (GDPA) and the National Medicines and Healthcare Products Regulatory Authority (NMHRA, established in 2019), functions as Afghanistan’s national regulator for human and veterinary medicines, biologicals and vaccines, medical devices and IVDs, cosmetics, traditional and complementary medicines, pharmacy practice, controlled substances, and clinical trials. Its jurisdiction spans all 34 provinces via the Provincial Public Health Directorates.

Headquartered in Kabul, the MoPH/NMHRA sets rules for market authorization, import licensing, distribution control, pharmacovigilance, and post-market actions. The regulator also coordinates with public health programs such as immunization, tuberculosis, and polio eradication, ensuring that life-saving products continue to flow despite complex logistics and intermittent security constraints.

Operational reality since August 2021 has required pragmatic reliance and recognition mechanisms to sustain supply. International agencies, including WHO and UNICEF, have maintained humanitarian operations, and the regulator interfaces daily with these programs to prioritize essential medicines, vaccines, and maternal–child health commodities.

Manufacturers, importers, distributors, and humanitarian sponsors must therefore navigate a framework that combines domestic legal instruments with internationally recognized standards and evidence. Afghan-domiciled manufacturers, foreign certificate holders, pooled UN procurement channels, and NGOs remain subject to registration, quality verification, and oversight, even where expedited or exceptional routes apply.

MoPH/NMHRA operates under the Medicine Law 2008, the Public Health Law, anti-narcotics legislation, pharmacy regulations, ministerial and director-level decrees, and procedural guidance issued by GDPA and NMHRA. In quality control and specifications, the authority recognizes major pharmacopoeias, including the British Pharmacopoeia, United States Pharmacopeia, European Pharmacopoeia, the WHO International Pharmacopoeia, and widely used regional texts such as the Indian, Pakistani, and Iranian pharmacopoeias.

In practice, Afghanistan leverages reliance and recognition to safeguard access while preserving public health protections. WHO-listed products, including vaccines, benefit from a mature reliance route where documentation from stringent authorities and procurement agencies shortens national review cycles. UN procurement and emergency programs often coordinate with regulators to sequence import permits, sampling, and lot release in parallel to field deployment of supplies.

For medicines and biologicals, core data expectations align with ICH practice for quality, safety, and efficacy, with a strong emphasis on stability appropriate to hot and dry climates. For medical devices and IVDs, manufacturers are expected to demonstrate conformity to essential principles, supported by an ISO 13485 quality system and risk management per ISO 14971. Afghanistan’s authority relies frequently on foreign approvals and WHO documentation to calibrate national decisions.

Controlled substances follow anti-narcotics provisions with import quotas, secure storage, and recordkeeping. Pharmacy practice oversight, pharmacovigilance, and quality surveillance complete the regulatory picture, enabling the authority to respond to substandard and falsified products via targeted investigations and market withdrawals.

Afghanistan applies several workable pathways to enable supply while preserving safety and quality. Essential medicines and widely used generics can proceed via abridged reviews when supported by international approvals or WHO listings. Originators and complex biologicals typically undergo fuller evaluation, with targeted reliance on stringent decisions where feasible. Vaccines approved or prequalified by WHO often follow reliance, accompanied by national lot release and post-shipment sampling.

Humanitarian programs may request expedited permits or temporary authorizations during emergencies, enabling time-bound importation with minimum critical documentation while full files are completed. For medical devices and IVDs, classification-driven pathways range from notification for low-risk products to formal registration for higher-risk classes, with evidence anchored in essential-principles conformity, QMS certificates, and safety–performance data.

Across all categories, expect to submit legalized company credentials, certificates of analysis, pharmacopoeial compliance statements, stability data suitable for hot climates, labels and instructions in Pashto, Dari, and English where required, and proof of foreign regulatory status or procurement agency eligibility. Sponsors should be prepared for provincial sampling, central laboratory testing, and coordination of lot release with public health program timelines.

For device and IVD files, map evidence to the essential principles and the regulator’s risk expectations, then cross-reference foreign approvals to streamline assessment. A clear gap analysis against Afghan labeling and language requirements reduces back-and-forth and protects delivery schedules for program-critical shipments.

Sponsors should pre-coordinate with national laboratories on sampling logistics and ensure that lot traceability in import documentation matches labels and certificates. Where reliance is used, submit the complete foreign decision package and align its conditions of use with Afghan clinical practice to minimize post-approval variations.

Importation requires valid licenses, product-level permissions, and, where applicable, shipment-specific approvals aligned to public health program calendars. Expect documentary verification at the border, with targeted post-clearance sampling coordinated by MoPH/NMHRA and provincial health directorates. For vaccines and biologics, cold chain evidence is scrutinized, and lot release proceeds alongside field deployment to avoid expiry-related wastage.

Manufacturing quality is assessed through internationally issued GMP certificates, inspection reports, and track records. Afghanistan is not a PIC/S authority, yet it frequently recognizes GMP evidence from stringent or PIC/S-participating regulators and from WHO GMP assessments. For sterile products, the authority may reference EU GMP Annex 1 and WHO guidance to judge aseptic system maturity, environmental controls, and contamination risk management.

Distribution quality hinges on GDP-aligned storage, transport validation for Route of Supply, and documented temperature control from the port of entry to provincial warehouses and health facilities. Sponsors must maintain robust complaint handling and pharmacovigilance with clear national contacts. When serious quality defects emerge, MoPH/NMHRA coordinates targeted market withdrawals while maintaining continuity of care for constrained therapeutic classes.

MoPH/NMHRA expects labeling and patient information to be intelligible to Afghan patients and providers. Pashto and Dari are the principal languages for end-user content, and English is widely accepted for technical components. Over-stickering or leaflets can bridge language gaps for imported product, provided they are accurate, durable, and authorized as part of the national approval.

Medicines must align to recognized pharmacopoeial monographs where applicable, with validated methods and system suitability adapted to local laboratory capability. Devices and IVDs must present clear instructions for use, symbols, and warnings that can be understood in low-resource settings. Where usability risks are high, ensure that pictograms and critical steps are unambiguous to reduce misuse.

Afghanistan spans ICH climatic Zones IVa and IVb, with arid and high-altitude conditions. Stability programs should therefore rely on Zone IV data sets, humidity and thermal cycling justifications, and packaging suitable for dusty, hot environments. Cold chain products must include transport validation, data logger records, and contingency procedures for road closures and power interruptions at provincial storage sites.

For devices and IVDs, the regulator follows a risk-based approach broadly aligned with international practice. Low-risk products may proceed via notification or listing, while higher-risk classes require formal registration with technical assessment. Evidence maps to essential principles, and submissions that cross-reference technical files used for CE or other stringent clearances tend to move faster.

Quality management is anchored in ISO 13485 with documented design controls, supplier management, and production traceability. Risk management should align with ISO 14971, demonstrating acceptable residual risk in Afghan use scenarios, including temperature swings, variable electricity supply for powered devices, and user training constraints. For usability, align human factors and user-interface safety with IEC 62366-1 and provide field-adapted IFUs.

Combination products are treated case-by-case, with the primary mode of action determining the lead pathway. Where a medicinal component dominates, prepare medicine-quality modules and device performance and safety annexes. Conversely, device-led combinations should present complete technical files, biocompatibility and sterility assurance evidence, and clear delineation of medicinal constituents.

MoPH/NMHRA oversees clinical investigations and requires ethics approval prior to human enrollment. Protocols should address Afghan clinical practice, site capability, consent in local languages, and safety reporting compatible with national pharmacovigilance systems. For medical devices, site training and maintenance plans are critical when deploying technology to facilities with variable infrastructure.

Clinical-quality expectations align with ICH Good Clinical Practice, including robust monitoring and data integrity, and for devices with ISO 14155. Sponsors should confirm data collection methods that endure connectivity gaps and ensure source data verification is feasible when study sites are geographically dispersed or security conditions limit travel.

During outbreaks and disasters, humanitarian access pathways permit temporary or emergency use authorizations with essential safeguards. These routes prioritize urgent public health needs while requiring the progressive completion of data packages. Donor-funded deployments must still maintain safety reporting, complaint handling, and traceability to enable targeted field corrections or withdrawals if risks emerge.

Afghanistan’s supply ecosystem is shaped by land borders with Pakistan, Iran, Turkmenistan, Uzbekistan, Tajikistan, and by trade from India, China, Turkey, and the Russian Federation. Cross-border flows and refugee movements create both opportunities for regulatory cooperation and pressures from informal channels. MoPH/NMHRA responds with reliance on trusted approvals, increased sampling, and collaboration with public health partners to prioritize essential commodities.

Where products already hold established approvals in neighboring jurisdictions or by stringent authorities, Afghan decisions often give weight to that evidence. Donor programs further structure supply by channeling procurement through prequalified manufacturers, using quality agreements and performance metrics to guard against lapses. Sponsors should anticipate additional verification steps for goods transiting multiple territories or free zones.

Substandard and falsified medicines remain a persistent threat along porous borders. Robust serialization, tamper-evident packaging, and secure chain-of-custody practices materially reduce risk, even if national UDI or serialization mandates are not fully in force. Clear field verification procedures and complaint escalation pathways help provincial authorities act quickly when anomalies surface.

Many delays stem from underestimating Afghan climatic and linguistic realities. Dossiers assembled for temperate markets, or English-only leaflets intended for clinical environments with scarce translation support, tend to require rework. Stability and packaging that do not tolerate high heat, dust, and transport shocks can stall lot release and trigger field complaints.

Sponsors also misread reliance as a waiver of local verification. Even when WHO or stringent decisions are recognized, MoPH/NMHRA will verify labeling, import documentation, and samples, and can impose conditions of use tailored to Afghan practice. Build time for legalization steps and for coordinating sampling with provincial rollouts, especially for temperature-sensitive shipments.

• Submitting Zone II stability data without a scientific justification for Zone IV conditions
• Omitting Pashto or Dari content on labels and leaflets where local-language communication is necessary
• Assuming donor catalog eligibility replaces national authorization and lot verification
• Providing incomplete Certificates of Pharmaceutical Product or inconsistent batch identifiers across documents
• Under-documenting GDP controls and route-specific temperature validation for inland transport
• Weak national contact details for complaints and safety reporting, impeding timely field action

Prevention hinges on early gap analysis against Afghan expectations, multilingual labeling plans, and supply-chain validation for the intended route. Treat reliance as a tool to streamline review, not a substitute for national controls. Maintain a contemporaneous change log so that any foreign post-approval variations are reflected promptly in Afghan files and in-market materials.

Achieving reliable Afghan supply requires synchronized control of documents, labeling, stability evidence, import documentation, and temperature records. V5 orchestrates these elements so cross-functional teams can keep dossiers synchronized to Afghan requirements while meeting donor deadlines. Sponsors can map international evidence to national checklists, ensuring reliance packages still satisfy local verification needs.

With V5, manufacturers and humanitarian partners unify labeling content across Pashto, Dari, and English, link stability studies to targeted Zone IV justifications, and embed import lot data, Certificates of Analysis, and cold-chain traces into release workflows. Device teams attach ISO 14971 risk files and usability evidence to the exact marketed configurations deployed in Afghan facilities.

Operationally, V5 aligns warehouse and field movements with traceable lots and complaint handling so that any suspected substandard or falsified product can be contained rapidly without stalling essential programs. Audit trails, change control, and supplier oversight features help keep reliance-based approvals aligned with ongoing international variations.